滨会生物携带“以毒攻毒治癌攻略”递表港交所

Core Viewpoint - The company Binhui Biotechnology is seeking to go public on the Hong Kong Stock Exchange, despite having no approved products, no sales revenue, and continuous losses, due to its HSV-2 oncolytic virus candidate drug entering Phase III clinical trials, attracting significant capital interest [1][3]. Company Overview - Binhui Biotechnology focuses on developing oncolytic virus therapies, specifically using the HSV-2 virus, which is believed to have better safety and greater gene-carrying capacity compared to the more common HSV-1 [5]. - The founder, Liu Binlei, has over 30 years of experience in tumor immunology and was involved in the development of the first FDA-approved oncolytic virus drug, IMLYGIC [4]. Market Potential - The global oncolytic virus market is projected to reach approximately $871 million in 2024, with the Chinese market estimated at around 45.3 million RMB. By 2030, the global market could grow to $7.5 billion, and the Chinese market may expand to 9.2 billion RMB [5]. Product Pipeline - Binhui has five products in various stages of development, with BS001 being the first HSV-2 oncolytic virus candidate to enter Phase III trials globally, and BS006 being the first bispecific antibody oncolytic virus currently in Phase I trials in the U.S. [7][8]. - BS001 has shown promising clinical data, with one-year and two-year overall survival rates of 91.0% and 72.0%, respectively, in melanoma patients [7]. Financial Performance - The company has reported cumulative losses exceeding 520 million RMB, with revenues from research services and reagent sales being minimal, indicating a "high investment, zero revenue" situation [9]. - As of June 30, 2025, Binhui had cash and equivalents of 166 million RMB, sufficient to cover operational needs for at least 12 months [9]. Investment and Financing - Binhui has completed seven rounds of financing, raising a total of 1.04 billion RMB, with significant early investments from local capital in Wuhan [10]. - The company's valuation has fluctuated significantly, with early investors experiencing both gains and losses in their share transfers [11]. Listing Journey - Binhui's path to listing has been complicated, having explored various markets including the Hong Kong Stock Exchange, STAR Market, and Beijing Stock Exchange before finally submitting its application to the Hong Kong Stock Exchange in September 2025 [12].